Association between human herpesvirus infection and cervical carcinoma: a systematic review and meta-analysis.
Cervical cancer
Epstein-Barr virus
Herpes simplex virus type 2
Human herpesvirus
Meta-analysis
Precancerous cervical lesions
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
04 Dec 2023
04 Dec 2023
Historique:
received:
02
10
2023
accepted:
06
11
2023
medline:
6
12
2023
pubmed:
5
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
Cervical cancer (CC) is one of the most common gynecologic tumors among women around the world. Although the etiological role of human papillomavirus (HPV) in CC is well established, other factors in CC carcinogenesis remains unclear. Here, we performed a systematic review and meta-analysis to explore the association between infections of human herpesvirus (HHVs) and CC risk. Embase and PubMed databases were utilized to search the relevant studies. The revised JBI Critical Appraisal Tool was used to assess the quality of the included studies. Prevalence and odds ratios (ORs) with 95% confidence intervals (CI) were calculated to evaluate the association between viral infection and CC or precancerous cervical lesions (PCL). Totally 67 eligible studies involving 7 different HHVs were included in meta-analysis. We found an increased risk of CC or PCL that was associated with the overall infection of HHVs (CC, OR = 2.74, 95% CI 2.13-3.53; PCL, OR = 1.95, 95% CI 1.58-2.41). Subgroup analysis showed a trend towards positive correlations between herpes simplex virus type 2 (HSV-2) infection and CC (OR = 3.01, 95% CI 2.24 to 4.04) or PCL (OR = 2.14, 95% CI 1.55 to 2.96), and the same is true between Epstein-Barr virus (EBV) infection and CC (OR = 4.89, 95% CI 2.18 to 10.96) or PCL (OR = 3.55, 95% CI 2.52 to 5.00). However, for HSV-1 and cytomegalovirus (HCMV), there was no association between viral infection and CC or PCL. By contrast, the roles of HHV-6, HHV-7, and Kaposi sarcoma-associated herpesvirus (KSHV) in cervical lesions were unclear due to the limited number of studies. This study provided evidence that HHVs infection as a whole increase the risk of CC incidence. In addition, some types of HHVs such as EBV and HSV-2 may serve as potential targets in the development of new interventions or therapeutic strategies for cervical lesions.
Sections du résumé
BACKGROUND
BACKGROUND
Cervical cancer (CC) is one of the most common gynecologic tumors among women around the world. Although the etiological role of human papillomavirus (HPV) in CC is well established, other factors in CC carcinogenesis remains unclear. Here, we performed a systematic review and meta-analysis to explore the association between infections of human herpesvirus (HHVs) and CC risk.
METHODS
METHODS
Embase and PubMed databases were utilized to search the relevant studies. The revised JBI Critical Appraisal Tool was used to assess the quality of the included studies. Prevalence and odds ratios (ORs) with 95% confidence intervals (CI) were calculated to evaluate the association between viral infection and CC or precancerous cervical lesions (PCL).
RESULTS
RESULTS
Totally 67 eligible studies involving 7 different HHVs were included in meta-analysis. We found an increased risk of CC or PCL that was associated with the overall infection of HHVs (CC, OR = 2.74, 95% CI 2.13-3.53; PCL, OR = 1.95, 95% CI 1.58-2.41). Subgroup analysis showed a trend towards positive correlations between herpes simplex virus type 2 (HSV-2) infection and CC (OR = 3.01, 95% CI 2.24 to 4.04) or PCL (OR = 2.14, 95% CI 1.55 to 2.96), and the same is true between Epstein-Barr virus (EBV) infection and CC (OR = 4.89, 95% CI 2.18 to 10.96) or PCL (OR = 3.55, 95% CI 2.52 to 5.00). However, for HSV-1 and cytomegalovirus (HCMV), there was no association between viral infection and CC or PCL. By contrast, the roles of HHV-6, HHV-7, and Kaposi sarcoma-associated herpesvirus (KSHV) in cervical lesions were unclear due to the limited number of studies.
CONCLUSIONS
CONCLUSIONS
This study provided evidence that HHVs infection as a whole increase the risk of CC incidence. In addition, some types of HHVs such as EBV and HSV-2 may serve as potential targets in the development of new interventions or therapeutic strategies for cervical lesions.
Identifiants
pubmed: 38049836
doi: 10.1186/s12985-023-02234-5
pii: 10.1186/s12985-023-02234-5
pmc: PMC10696706
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
288Subventions
Organisme : Program of Medical Discipline Leader in Yunnan Health System
ID : D-2019027
Organisme : Program of Medical Discipline Leader in Yunnan Health System
ID : D-2019023
Organisme : Chinese Academy of Medical Sciences Initiative for Innovative Medicine
ID : 2021-I2M-1-004
Organisme : Technological Innovation Talents of Yunnan Province
ID : 2019HB044
Informations de copyright
© 2023. The Author(s).
Références
J Med Virol. 2020 Aug;92(8):1246-1252
pubmed: 31925791
J Clin Pathol. 2020 Jan;73(1):30-34
pubmed: 31315894
Am J Epidemiol. 1974 Aug;100(2):130-5
pubmed: 4368955
Front Cell Infect Microbiol. 2021 Sep 07;11:703259
pubmed: 34557425
Cancer Res. 1989 Sep 1;49(17):4925-8
pubmed: 2547521
J Virol Methods. 2001 Apr;93(1-2):23-32
pubmed: 11311340
Am J Epidemiol. 1973 Jul;98(1):1-9
pubmed: 4131112
Science. 1968 Sep 20;161(3847):1255-6
pubmed: 4299806
Cancer Res. 1977 May;37(5):1301-6
pubmed: 192446
Pol J Microbiol. 2004;53(2):95-9
pubmed: 15478354
Gynecol Oncol. 1993 Aug;50(2):168-72
pubmed: 8397152
J Natl Cancer Inst. 1974 Feb;52(2):369-76
pubmed: 4816000
Am J Epidemiol. 2002 Oct 15;156(8):687-92
pubmed: 12370156
Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2541-50
pubmed: 21994401
J Clin Invest. 2020 Jul 1;130(7):3361-3369
pubmed: 32364538
BMJ. 1996 Mar 2;312(7030):537-9
pubmed: 8595281
Pathogens. 2020 Aug 21;9(9):
pubmed: 32839399
Int J Cancer. 1995 Feb 8;60(4):438-42
pubmed: 7829255
BMC Cancer. 2020 Jun 1;20(1):493
pubmed: 32487043
Int J Cancer. 1991 Mar 12;47(5):711-6
pubmed: 1848537
Proc R Soc Lond B Biol Sci. 1980 Nov 19;210(1180):411-21
pubmed: 6109302
Gynecol Oncol. 2018 Feb;148(2):317-328
pubmed: 29021084
Int J Cancer. 1981 May 15;27(5):669-77
pubmed: 6270022
Braz J Microbiol. 2012 Apr;43(2):744-53
pubmed: 24031886
Clin Infect Dis. 1999 Dec;29(6):1584-5
pubmed: 10585826
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Acta Biochim Pol. 2009;56(2):337-42
pubmed: 19499088
J Clin Pathol. 1993 Oct;46(10):931-5
pubmed: 8227411
Diagn Pathol. 2015 Jun 02;10:59
pubmed: 26032781
Hum Pathol. 2000 Mar;31(3):318-26
pubmed: 10746674
J Med Virol. 2012 Dec;84(12):1920-7
pubmed: 23080497
Cancer Res. 1976 Jun;36(6):1910-4
pubmed: 1268845
J Med Virol. 2013 Aug;85(8):1409-13
pubmed: 23765777
APMIS. 1992 Jul;100(7):598-604
pubmed: 1322678
J Clin Microbiol. 2011 Jul;49(7):2435-9
pubmed: 21525227
Virol J. 2013 Nov 19;10:340
pubmed: 24252325
Sex Transm Dis. 2018 Oct;45(10):666-672
pubmed: 29664764
J Med Virol. 2000 Dec;62(4):410-5
pubmed: 11074467
J Med Virol. 1989 Feb;27(2):131-6
pubmed: 2537883
Cancer. 1972 Jul;30(1):68-74
pubmed: 4339261
Gynecol Oncol. 1984 Jul;18(3):349-58
pubmed: 6086470
Pathol Int. 1997 Aug;47(8):507-11
pubmed: 9293529
Arch Gynecol Obstet. 2014 Dec;290(6):1059-66
pubmed: 25030659
Am J Epidemiol. 1982 May;115(5):729-35
pubmed: 6282116
Cancer. 1974 Jan;33(1):147-52
pubmed: 4810088
J Med Virol. 2019 Mar;91(3):450-456
pubmed: 30307626
Nat Rev Cancer. 2010 Dec;10(12):878-89
pubmed: 21102637
Microorganisms. 2022 Apr 24;10(5):
pubmed: 35630333
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Int J Gynecol Cancer. 2005 Mar-Apr;15(2):312-8
pubmed: 15823118
Int J Cancer. 1977 Feb 15;19(2):167-71
pubmed: 190174
Am J Cancer Res. 2016 Jun 01;6(6):1371-83
pubmed: 27429850
Hum Vaccin Immunother. 2017 Aug 3;13(8):1839-1843
pubmed: 28594305
Expert Rev Anti Infect Ther. 2020 Sep;18(9):865-874
pubmed: 32552158
Virol J. 2021 Jul 10;18(1):144
pubmed: 34246302
J Low Genit Tract Dis. 2003 Jul;7(3):187-93
pubmed: 17051067
Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51
pubmed: 16950017
Cancer Causes Control. 1992 Jul;3(4):333-8
pubmed: 1617120
Dis Markers. 2007;23(4):213-27
pubmed: 17627057
Asian Pac J Cancer Prev. 2012;13(1):339-42
pubmed: 22502697
Oncol Rep. 2009 Feb;21(2):403-5
pubmed: 19148514
Sex Transm Dis. 1996 Mar-Apr;23(2):138-44
pubmed: 8919741
Int J Gynecol Pathol. 2006 Jan;25(1):42-7
pubmed: 16306783
Int J Cancer. 1994 Feb 1;56(3):358-63
pubmed: 8314322
Front Microbiol. 2023 Feb 09;14:1116143
pubmed: 36846758
Int J Cancer. 1981 Nov 15;28(5):535-42
pubmed: 6273337
Cancer Res. 1974 May;34(5):1111-7
pubmed: 4366985
J Virol Methods. 1997 Jun;66(1):5-14
pubmed: 9220385
Int J Cancer. 1985 Jan 15;35(1):19-26
pubmed: 2981778
J Med Virol. 2008 Jan;80(1):147-53
pubmed: 18041029
Epidemiol Infect. 1988 Jun;100(3):445-65
pubmed: 2837405
J Clin Virol. 2015 Dec;73:70-76
pubmed: 26551071
Int J Gynaecol Obstet. 1976;14(3):209-12
pubmed: 13005
Cell Immunol. 1978 Nov;41(1):86-102
pubmed: 82488
Int J Cancer. 1984 Jan 15;33(1):61-6
pubmed: 6319297
Int J Cancer. 1973 Nov 15;12(3):626-30
pubmed: 4364794
Acta Pathol Microbiol Immunol Scand B. 1983 Jun;91(3):205-7
pubmed: 6308950
Virus Res. 2017 Mar 2;231:139-147
pubmed: 27826043
Gynecol Oncol. 1980 Aug;10(1):18-25
pubmed: 6249698
J Clin Epidemiol. 2011 Apr;64(4):383-94
pubmed: 21195583
Arch Virol. 1977;54(3):211-21
pubmed: 196578
Br J Obstet Gynaecol. 1981 Nov;88(11):1130-4
pubmed: 6271164
Int J Cancer. 1997 Dec 10;73(6):781-5
pubmed: 9399651